Syremis Therapeutics
PrivateLast Round
Series A
Dec 18, 2025
Total Funding Raised
$165M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Syremis Therapeutics is a biopharmaceutical company that develops novel medicines for mental health disorders such as schizophrenia, major depressive disorder, and bipolar depression.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Syremis Therapeutics Comparables
Compare Syremis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Clexio Biosciences | 78% | |
| Draig Therapeutics | 78% | |
| Leal Therapeutics | 74% |
Syremis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 18, 2025 |
Key People
Founding team and executive leadership
Syremis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bain Capital Life Sciences | Series A |
| Pictet Group | Series A |
| GV | Series A |
| QVT Financial | Series A |
| Third Rock Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 22, 2026
Grew 19% QoQ, from 32 to 38 employees.
- Dec 18, 2025
$165M Series A round completed.
Recent news
Latest coverage and updates
- hiresJun 16, 2026
Syremis Therapeutics Ltd. hired Aaron Koenig as Chief Medical Officer on Jun 16th '26.
Syremis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Syremis Therapeutics's valuation, stock price, and market status.
Is Syremis Therapeutics a public or private company?
Syremis Therapeutics is a private company.
What is the current stock price of Syremis Therapeutics?
Syremis Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Syremis Therapeutics worth (valuation)?
Valuation information for Syremis Therapeutics is not publicly available.
Can I buy Syremis Therapeutics stock?
Syremis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Syremis Therapeutics's last funding round?
Syremis Therapeutics's most recent funding round was Series A on December 18, 2025.
Who are the main investors in Syremis Therapeutics?
Key investors in Syremis Therapeutics include Third Rock Ventures.
Will Syremis Therapeutics IPO soon?
No public IPO plans have been announced for Syremis Therapeutics.
How can I track Syremis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Syremis Therapeutics's secondary market activity and sign up for updates.